Skip to main content

Table 1 Breast cancer risk in relation to selected SNPs

From: TNRC9 rs12443621 and FGFR2 rs2981582 polymorphisms and breast cancer risk

SNP Genotypes Cases Controls χ 2a P a ORa 95 % CIa Adjusted ORb 95 % CIb
TNRC9 AA 10 (11.2) 79 (18.8) 8.100 0.017 1.0   1.0  
rs12443621 AG 24 (22.86) 94 (24.61)    2.017 0.910–4.471 0.621 0.075–5.129
  GG 71 (67.62) 209 (54.71)    2.684 1.318–5.463 1.569 0.233–10.556
AG + GG   95 (90.48) 303 (79.32)       
G allele   0.79 0.670       
FGFR2 GG 50 (47.62) 120 (31.41) 10.203 0.006 1.0   1.0  
rs2981582 GA 27 (25.71) 146 (38.22)    0.444 0.262–0.752 0.557 0.141–2.199
  AA 28 (26.67) 116 (30.37)    0.579 0.342–0.983 0.559 0.154–2.032
GA + AA   55 (52.38) 262 (68.59)       
A allele   0.395 0.495       
TNRC9 CC 76 (72.38) 250 (65.44) 1.791 0.408 1.0   1.0  
rs3803662 CT 21 (20) 96 (25.13)    0.720 0.420–1.232 0.304 0.075–1.241
  TT 8 (7.61) 36 (9.42)    0.731 0.326–1.640 0.008 0.001–0.01
CT + TT   29 (27.62) 132 (34.56)       
T allele   0.176 0.219       
LSP1 TT 85 (80.95) 272 (71.20) 4.310 0.116 1.0   1.0  
rs3817198 TC 18 (17.14) 93 (24.35)    0.619 0.354–1.085 0.059 0.159–2.183
  CC 2 (1.90) 17 (4.45)    0.376 0.085–1.663 0.00 0.00–0.00
TC + CC   20 (19.05) 110 (28.80)       
C allele   0.104 0.166       
  1. SNPs single nucleotide polymorphisms, TNRC9 trinucleotide-repeat-containing 9, FGFR2 fibroblast growth factor receptor 2, LSP1 leukocyte-specific protein 1, OR odds ratio, CI confidence interval.
  2. aTwo-sided χ 2 test
  3. bAge-adjusted